development of new treatment for myopic choroidal neovascularization

我研究了近视黄斑病变的长期发展模式。近视眼脉络膜新生血管（CNV）最常见的形态为漆状裂缝和斑片状萎缩。我确定2年玻璃体内贝伐单抗（IVB）和光动力治疗（PDT）对高度近视的CNV的结果。IVB后2年的平均最佳矫正视力（BCVA）较IVB前有显著改善。基线BCVA与PDT后2年的BCVA无统计学差异。IVB和PDT后2年伴有中央凹下CNV的chra发生率（80%）明显高于非中央凹下CNV。非中央凹下CNV的平均BCVA在IVB后2年显著改善。IVB对于非中央凹下CNV可能是一个有吸引力的选择，然而，对于位于中央凹下的CNV，一些其他的入路是必要的。

I investigated the long-term progression pattern of myopic maculopathy. The most commonly observed patterns of myopic choroidal neovascularization (CNV) were from lacquer cracks and patchy atrophy to CNV.I determine the 2-year results of intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) in highly myopic eyes with CNV. The mean best-corrected visual acuities (BCVA)2years after IVB was significantly improved from the BCVA before IVB. There was no statistically significant difference between baseline BCVA and the BCVA2years after PDT. The incidence rate of ChRA2years after IVB and PDT with subfoveal CNV was significantly higher (80%) than that of non-subfoveal CNV. The mean BCVA with non-subfoveal CNV was significantly improved2years after IVB. IVB might be an attractive option for the eyes with non-subfoveal CNV, however, some other approaches are necessary for subfoveally-located CNV.